Hyperkalemia
Hyperkalemia
Part of NephTimes
Advertisement
Victoria SochaHyperkalemia | February 5, 2024
The prevalence of hyperkalemia among individuals with chronic kidney disease (CKD) is 14% to 20%.
Read More
Victoria SochaHyperkalemia | February 5, 2024
Examining the effects of finerenone doses in patients with chronic kidney disease (CKD) and type 2 diabetes.
Victoria SochaChronic Kidney Disease | February 5, 2024
When dietary potassium intake was examined within quartiles, there was a nonlinear association with AAC.
Victoria SochaHyperkalemia | February 5, 2024
Both hyperkalemia and hypokalemia are associated with muscle paralysis and potentially fatal cardiac arrhythmias.
Victoria SochaHyperkalemia | February 5, 2024
There are few data available on the adverse effect of hyperkalemia on progression of chronic kidney disease (CKD).
Victoria SochaHyperkalemia | February 5, 2024
Patients with hyperkalemia treated with SCZ have a higher rate of continuation of RAAS inhibition.
Victoria SochaHyperkalemia | February 5, 2024
Examining whether administration of patiromer would reduce the number of significant arrhythmia events.
Victoria SochaHyperkalemia | February 5, 2024
Training an artificial intelligence algorithm that can detect hyperkalemia from the surface electrocardiogram.
Victoria SochaHyperkalemia | February 5, 2024
There is an independent association between hyperkalemia and poor outcomes among individuals with chronic kidney disease.
Victoria SochaHyperkalemia | February 5, 2024
Guideline recommendations call for maintenance of RAASi therapy using novel antihyperkalemia treatment.
Victoria SochaHyperkalemia | February 5, 2024
At the 12-month follow-up, 100% of patients in the patiromer group remained on RAAS inhibitor therapy.
Victoria SochaHyperkalemia | February 5, 2024
Concerns related to hyperkalemia are key in patients with CKD who are receiving other hyperkalemia-inducing agents.
Victoria SochaHyperkalemia | February 5, 2024
Patients with chronic kidney disease (CKD) who develop hyperkalemia are at risk for serious adverse outcomes.
Victoria SochaHyperkalemia | February 5, 2024
Participants were randomized to placebo or SZC 5 grams once daily on nondialysis days.
Victoria SochaHyperkalemia | February 5, 2024
During an average follow-up of 3.9 years, 12.4% of patients (n=220,339) experienced at least one hyperkalemic episode.
Victoria SochaHyperkalemia | February 5, 2024
There were no statistically significant differences in the effect of oral potassium binder treatment at each timepoint.
Victoria SochaHyperkalemia | February 5, 2024
There was a five-fold higher risk of hyperkalemia with use of a steroidal MRA plus an ACEi or ARB.
Victoria SochaHyperkalemia | February 5, 2024
At 60 days, 48% of patients had a patiromer proportion of days covered >80%.
Victoria SochaHyperkalemia | February 5, 2024
Examining efficacy and safety of sacubitril/valsartan for patients with CKD.
Victoria SochaHyperkalemia | February 5, 2024
Medical costs in patients with hyperkalemia receiving SCZ therapy.
Advertisement
Advertisement
Advertisement
Latest News

February 27, 2024